Columbia Cornerstone Growth Fund Q4 2025 Portfolio Recap Analysis

This analysis is based on the Columbia Cornerstone Growth Fund Q4 2025 Quarterly Portfolio Recap [1] published on March 24, 2026, which provides insights into Q4 2025 market dynamics and highlights key portfolio performers.

The Russell 1000 Index posted a gain of

in Q4 2025, representing moderate positive returns that suggest steady rather than spectacular market performance during that quarter [1]. This performance context is important when evaluating the fund’s positioning and the broader market environment.

The quarter was notably characterized by a

away from mega-cap technology stocks—a significant departure from the concentration that had dominated previous periods. This rotation toward value stocks outpacing their growth counterparts indicates a healthy market broadening trend, historically associated with more sustainable bull markets [1][0].

Eli Lilly (LLY) was highlighted as a standout performer in the fund’s recap, driven by strong earnings stemming from its dominant position in obesity treatments [1]. This recognition aligns with the company’s exceptional fundamentals:

• Quarterly Revenue Growth
  : Revenue expanded from $12.73B in Q1 FY2025 to $19.29B in Q4 FY2025 [0]
• Earnings Performance
  : Q4 FY2025 EPS of $7.54 vs. $6.91 estimate (+9.12% surprise); Revenue of $19.29B vs. $17.94B estimate (+7.51% surprise) [0]
• Profitability Metrics
  : Net profit margin of 31.66%, operating margin of 45.56%, and ROE of 97.85% [0]
• Obesity Franchise
  : Accounts for 74.9% of revenue ($13.18B) from Cardiometabolic Health segment [0]

Market data reveals significant divergence between the Q4 2025 environment described in the event and current market conditions:

Index	Q4 2025 (Event)	Recent 30 Days	YTD
Russell 1000	+2.41%	—	—
S&P 500	—	-5.71%	-5.71%
NASDAQ	—	-6.19%	-6.19%
Dow Jones	—	-7.81%	-7.81%

This current weakness across all major indices (declining 5-8% over the past 30 trading days) suggests the broadening of leadership noted in Q4 2025 may have reversed, with defensive sectors now leading [0].

---

The Q4 2025 rotation from mega-cap technology toward value stocks represents a notable market regime shift. The “Magnificent Seven” concentration that characterized much of 2023-2024 gave way to more broad-based participation, which technical analysts historically view as a healthier market sign [1][0]. However, current sector performance data showing utilities (+2.88%), basic materials (+2.43%), and energy (+2.22%) leading indicates a

that contrasts with the Q4 2025 value-outperformance narrative [0].

Despite exceptional fundamental performance—strong earnings beats, expanding margins, and dominant market position in GLP-1 obesity treatments—Eli Lilly’s technical momentum has significantly weakened:

Metric	Value
Current Price	$899.32
Market Cap	$849.69B
P/E Ratio	39.19x
YTD Performance	-16.76%
1-Month Performance	-13.71%
3-Month Performance	-16.50%

This divergence between fundamentals and technical performance presents an interesting analytical puzzle [0].

---

: The P/E ratio of 39.19x and P/B of 30.43x indicate elevated valuations that may not fully reflect competitive pressures [0]. The recent -16.76% YTD decline may represent profit-taking after significant prior gains.

: With 74.9% of revenue derived from the cardiometabolic/weight loss segment, the company faces single-product dependency concerns [0].

:

• Novo Nordisk (Ozempic/Wegovy) competition continues intensifying
• Orfor (oral GLP-1) launch scheduled for April 2026 represents a key catalyst [2]

: A class action RICO lawsuit proceeding against Lilly regarding insulin pricing could result in significant damages [3].

: 66.7% of revenue originates from the U.S. market; international expansion through the $3B China investment is critical for future growth [0][4].

: Medicare coverage expansion for obesity drugs (expected H2 2026) is a major catalyst but remains subject to policy uncertainty [2].

• Current market weakness across all indices (down 5-8% in recent 30 days) suggests continued volatility
• Defensive sector rotation may indicate evolving risk-off sentiment
• The broadening of leadership noted in Q4 2025 appears to have reversed

---

The Columbia Cornerstone Growth Fund’s Q4 2025 portfolio recap provides valuable context for understanding market dynamics during that period. The key findings include:

1. Market Performance
   : Russell 1000 Index gained 2.41% in Q4 2025, reflecting moderate steady growth [1]

2. Leadership Broadening
   : Market leadership expanded beyond mega-cap technology stocks toward value stocks—a historically healthy market sign [1][0]

3. Eli Lilly Recognition
   : The fund highlighted Eli Lilly as a standout performer, driven by strong earnings from its dominant GLP-1 obesity treatment position (Zepbound, Mounjaro) [1][0]

4. Current Divergence
   : Current market conditions show significant weakness (all major indices down 5-8% over 30 days), with defensive sectors now leading—suggesting potential regime change from Q4 2025 [0]

5. Analyst Consensus on LLY
   : Buy rating with $1,280 price target (+42.3% upside), though recent HSBC downgrade to Reduce indicates mixed analyst sentiment [0][2]

The information synthesis suggests investors should monitor valuation levels, competitive dynamics in the obesity treatment market, and broader market regime changes when evaluating positions in highlighted performers like Eli Lilly.